The COHCCC Protocol Review and Monitoring System is implemented through the activities of its Cancer Protocol Review and Monitoring Committee (CPRMC). The CPRMC focuses on scientific merit, scientific priorities, and scientific progress of Cancer Center clinical research, working collaboratively with the Data and Safety Monitoring Committee (DSMC) in accordance with the COHCCC Data and Safety Monitoring Plan. The role of the CPRMC is to: 1) maintain and improve the quality of institutional clinical research; 2) prioritize clinical research conducted by Cancer Center members; and 3) provide a pathway for innovative clinical cancer research to access Cancer Center shared resources and protocol specific research support. Committee review and voting is required for all new trials, amendments, and annual continuation reviews. The scientific review process for new trials includes an evaluation of study design, scientific rationale, feasibility and biostatistical methodology. Annual continuation reviews include an examination of actual vs. expected accrual and continued relevance of the research question. The CPRMC provides a centralized mechanism for evaluating the scientific merit of all cancer clinical trials and prioritizes studies for access to COHCCC clinical trial resources. Funding is requested for partial salary support for the Chair of the CPRMC, the Director of Scientific and Safety Review, two Protocol Analysts and a Clerical Specialist supporting the work of protocol review and monitoring. All other remaining costs are covered by institutional funds.
It is of critical importance that the COHCCC have a mechanism for assuring adequate internal oversight of the scientific aspects of all cancer clinical trials. The PRMS addresses this. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344 |
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707 |
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816 |
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948 |
Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765 |
Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923 |
Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R |
Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123 |
Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55 |
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60 |
Showing the most recent 10 out of 1396 publications